AVITA Medical, Inc. (RCEL) - 10-K Summary
Business Context and Reporting Period
Company: AVITA Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: AVITA Medical is a therapeutic acute wound care company focused on the RECELL autologous cell harvesting technology for burns and full-thickness skin defects. The company expanded its portfolio in 2025 with the commercial launch of Cohealyx (dermal matrix) and the distribution of PermeaDerm (biosynthetic wound matrix). The company operates as a single reporting segment with the majority of revenue generated in the United States.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Total Revenues | $71,610 | $64,251 |
| Gross Profit | $58,816 | $55,157 |
| Gross Margin | 82.1% | 85.8% |
| Operating Loss | $(42,534) | $(56,593) |
| Net Loss | $(48,587) | $(61,845) |
| Cash & Cash Equivalents (End of Period) | $10,243 | $14,050 |
| Marketable Securities | $7,942 | $21,835 |
| Loan Facility (Fair Value) | $42,984 | $42,245 |
Note: The filing text does not provide a specific "Cash Flow from Operations" line item in the summary tables, but the Consolidated Statements of Cash Flows indicate Net cash used in operating activities was $(31,195) thousand for 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11% ($7.4 million) driven by deeper penetration in customer accounts, new accounts for traumatic/surgical wounds, and new product launches (Cohealyx).
- Margin Compression: Gross margin decreased from 85.8% to 82.1%. This was primarily due to product mix changes (revenue sharing on Cohealyx and PermeaDerm) and higher inventory reserves.
- Expense Reduction: Total operating expenses decreased 9% ($10.4 million). Sales and marketing expenses dropped 9% due to sales force reductions, and G&A expenses dropped 18% due to lower headcount and stock-based compensation.
- Loss Reduction: Net loss improved by 21% ($13.3 million) due to higher gross profit and lower operating expenses, partially offset by higher "Other expense, net" related to debt fair value changes.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed "substantial doubt" about the company's ability to continue as a going concern for the next twelve months due to recurring losses, negative cash flows, and debt obligations. Financial statements do not include adjustments that might result from this uncertainty.
- Debt Refinancing (Subsequent Event): On January 13, 2026, the company entered into a new $60 million credit facility with Perceptive Credit Holdings, refinancing its previous $40 million OrbiMed debt. The new facility includes a $50 million initial draw and a $10 million accordion feature. It carries a revenue covenant and requires a minimum cash balance of $5 million.
- Regulatory & Reimbursement:
- Received FDA approval for RECELL GO mini (Dec 2024) and CE Mark for RECELL GO (Sept 2025).
- CMS approved a New Technology Add-On Payment (NTAP) for RECELL for non-thermal full-thickness skin defects effective Oct 1, 2025, providing up to $4,875 additional reimbursement per case.
- Strategic Shifts: The company has paused commercial investment in the vitiligo indication due to limited reimbursement. Focus is shifting to acute wound care (burns, trauma, surgical) and international expansion via distributors.
- Risks: Key risks include the ability to meet revenue covenants under the new credit agreement, reliance on third-party distributors, supply chain disruptions, and the need for additional equity financing which could cause dilution.
Investor Verification Checklist
- Debt Covenants: Verify the company's ability to meet the new trailing twelve-month (TTM) revenue covenants under the Perceptive Credit Agreement (initially $68.5M for Q1 2026).
- Liquidity Runway: Assess the sufficiency of the $18.2 million in cash/securities combined with the new $50 million debt draw to fund operations until profitability is achieved.
- Product Mix Impact: Monitor the long-term impact of revenue-sharing agreements on Cohealyx and PermeaDerm on overall gross margins.
- Reimbursement Stability: Track the adoption of the new CMS NTAP code and the stability of CPT codes for RECELL procedures following the 2025 MAC pricing updates.
- Equity Dilution: Review the terms of the new credit facility regarding warrant issuance and the potential need for future equity raises given the "going concern" qualification.